CLBS Caladrius Biosciences Inc.

3.30
-0.00  -0%
Previous Close 3.30
Open 3.30
Price To book 0.59
Market Cap 31223531
Shares 9,470,860
Volume 8,861
Short Ratio 0.84
Av. Daily Volume 55,690

SEC filingsSee all SEC filings

  1. 8-K - Current report 171191049
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 171190846
  3. 8-K - Current report 171169041
  4. 8-K - Current report 171095973
  5. 424B3 - Prospectus [Rule 424(b)(3)] 171094615

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 top-line data due 1Q 2018.
CLBS03
Type 1 diabetes
Announced January 2016 that Phase 3 trial has been discontinued
CLBS20
Metastatic melanoma

Latest News

  1. Caladrius Biosciences Reports 2017 Third Quarter Results
  2. Caladrius Biosciences, Inc. to Host Earnings Call
  3. What Is Caladrius Biosciences Inc’s (CLBS) Share Price Doing?
  4. Caladrius Biosciences to Host 2017 Third Quarter Business Update Conference Call on November 9, 2017 at 4:30 p.m. Eastern Time
  5. Caladrius Biosciences to Participate at Upcoming November Conferences
  6. How Long Will Loss-Making Caladrius Biosciences Inc (CLBS) Survive?
  7. Caladrius Biosciences Awarded Approximately $2 Million NIH Grant to Support Clinical Study of CLBS14 in Patients with Coronary Microvascular Dysfunction
  8. Caladrius Biosciences to Participate at the 2017 Cell & Gene Meeting on the Mesa
  9. The Zacks Analyst Blog Highlights: Caladrius Biosciences, Orexigen Therapeutics, Sangamo Therapeutics and Syndax Pharmaceuticals
  10. Why These 4 Biotech Stocks May Not Lose Momentum Soon
  11. Type 1 Diabetes May Soon Meet Its Match
  12. Caladrius Biosciences to Participate at Upcoming September Conferences
  13. Caladrius Biosciences Announces Enrollment of the 70th Subject in the Phase 2 T-Rex Clinical Trial of CLBS03 for Type 1 Diabetes
  14. Investor Network: Caladrius Biosciences, Inc. to Host Earnings Call
  15. ETFs with exposure to Caladrius Biosciences, Inc. : July 12, 2017
  16. Invetech and Caladrius Biosciences Receive 2017 Good Design Award® for Design of a Counterflow Centrifuge Device for use in the Development of Cell Therapies

SEC Filings

  1. 8-K - Current report 171191049
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 171190846
  3. 8-K - Current report 171169041
  4. 8-K - Current report 171095973
  5. 424B3 - Prospectus [Rule 424(b)(3)] 171094615
  6. EFFECT - Notice of Effectiveness 171093203
  7. CORRESP [Cover] - Correspondence
  8. S-3/A [Amend] - Registration statement under Securities Act of 1933 171083612
  9. S-3 - Registration statement under Securities Act of 1933 171069890
  10. 8-K - Current report 171067434